Joshua Lang, MD, MS discusses how emerging biomarkers may help personalize treatment decisions while highlighting barriers to precision oncology in prostate cancer.
Joshua Lang, MD, MS
Advertisement
Articles by Joshua Lang, MD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Testosterone deficiency: FAQs from the AUA guideline
2
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
3
From hype to practice: Urologists assess AI's real impact
4
PTEN Testing Strategies for Newly Diagnosed mHSPC
5